HC Wainwright Issues Positive Forecast for Bicara Therapeutics (NASDAQ:BCAX) Stock Price

Bicara Therapeutics (NASDAQ:BCAX) had its price objective upped by HC Wainwright from $42.00 to $45.00 in a research report sent to investors on Monday morning,Benzinga reports. The brokerage currently has a buy rating on the stock.

A number of other brokerages have also recently weighed in on BCAX. Rodman & Renshaw initiated coverage on Bicara Therapeutics in a research report on Tuesday, November 5th. They issued a “buy” rating and a $48.00 price target for the company. Morgan Stanley assumed coverage on Bicara Therapeutics in a research note on Tuesday, October 8th. They set an “overweight” rating and a $35.00 price objective for the company. TD Cowen initiated coverage on Bicara Therapeutics in a research report on Tuesday, October 8th. They set a “buy” rating on the stock. RODMAN&RENSHAW raised Bicara Therapeutics to a “strong-buy” rating in a research note on Tuesday, November 5th. Finally, Stifel Nicolaus initiated coverage on Bicara Therapeutics in a research report on Tuesday, October 8th. They set a “buy” rating and a $47.00 price objective for the company. Six analysts have rated the stock with a buy rating and one has given a strong buy rating to the company. According to data from MarketBeat.com, the company has a consensus rating of “Buy” and an average target price of $43.75.

Bicara Therapeutics Stock Performance

NASDAQ BCAX opened at $11.76 on Monday. Bicara Therapeutics has a 52 week low of $11.10 and a 52 week high of $28.09. The business’s fifty day moving average is $16.65.

Bicara Therapeutics (NASDAQ:BCAX) last posted its earnings results on Tuesday, November 12th. The company reported ($1.60) earnings per share for the quarter, missing the consensus estimate of ($0.46) by ($1.14). Sell-side analysts expect that Bicara Therapeutics will post -2.59 earnings per share for the current fiscal year.

Institutional Trading of Bicara Therapeutics

Several institutional investors and hedge funds have recently made changes to their positions in the business. Spire Wealth Management acquired a new stake in Bicara Therapeutics in the fourth quarter worth $31,000. SG Americas Securities LLC bought a new position in Bicara Therapeutics in the fourth quarter valued at approximately $147,000. Cinctive Capital Management LP acquired a new position in shares of Bicara Therapeutics in the third quarter valued at approximately $229,000. Barclays PLC acquired a new position in Bicara Therapeutics in the 3rd quarter worth $255,000. Finally, Jane Street Group LLC acquired a new stake in shares of Bicara Therapeutics in the 3rd quarter valued at about $309,000.

Bicara Therapeutics Company Profile

Bicara Therapeutics Inc, a clinical-stage biopharmaceutical company, develops bifunctional therapies for solid tumors. Its lead program is ficerafusp alfa, a bifunctional antibody that combines an epidermal growth factor receptor (EGFR) directed monoclonal antibody with a domain that binds to human transforming growth factor beta (TGF-b) for the treatment of solid tumors.